Blog - Diabetes News
Dexcom State of Type 2 Report
A growing type 2 epidemic
Diabetes is a growing public health challenge, affecting approximately 4.6 million people in the UK and placing significant pressure on healthcare systems.1 Of those living with diabetes, 90%1 have type 2 diabetes and the NHS spends approximately £10 billion annually on diabetes care – 9% of its budget.2
The picture in Europe, the Middle East and North Africa is similar. In Europe, approximately 61 million adults live with diabetes, with numbers projected to reach 69 million by 2045.2 In the Middle East and North Africa (MENA) region, the situation is even more critical, with prevalence expected to rise from 73 million in 2021 to nearly 136 million by 20453 —the second highest increase globally. Across both regions, the vast majority (90%)4 of people with diabetes live with T2D.
- Diabetes UK. How many people in the UK have diabetes? Accessed April, 2025. www.diabetes.org.uk/about-us/about-the-charity/our-strategy/statistics
- National Institute for Health and Care Research. NHS programme linked to 20% reduction in risk of diabetes. Accessed April 2025. www.nihr.ac.uk/story/nhs-programme-linked-20-reduction-risk-diabetes
- Diabetes Federation. IDF Diabetes Atlas - 10th edition. 2021. 78-82.
- International Diabetes Federation. Type 2 diabetes. Accessed March, 2025. https://idf.org/about-diabetes/types-of-diabetes/type-2/
Key findings
HCPs prioritise tech over medication for the future of type 2 diabetes care
HCPs ranked access to CGM and education as more impactful than advancements in diabetes medications on the future of T2D care, with 52% of HCPs saying better access to CGM has the potential to positively help PWT2D to manage their condition in the next 10 years, compared with 38% who cited more effective medications.
HCPs View CGM as the Standard of Care
For insulin treated people living with type 2 diabetes, HCPs across Europe and the Middle East agreed CGM should be the standard of care, with 96% of HCPs saying those using multiple daily injections of insulin should receive CGM and 86% saying those relying on basal insulin should be offered CGM.
Diabetes knowledge is low prior to diagnosis and awareness of CGM is low
A significant finding from the Dexcom State of Type 2 Report was that across Europe and the Middle East, people generally had very little knowledge about type 2 diabetes prior to diagnosis, with 76% saying they knew nothing at all or only a little about the condition. The report also reveals a substantial gap in CGM awareness, with 51% of PWT2D either unaware of what a CGM device is or of how it could benefit them.
Did you know that you may be eligible for NHS funding for Dexcom?
Dexcom State of Type 2 UK Infographic
The infographic highlights some of the key findings and statistics for the UK.
Previous Reports
All non referenced information throughout this document is based on the Dexcom State of Type 2 report survey data. Dexcom, Data on File, 2025
Try a free Dexcom ONE+ sample now
Request a free 10-day sensor and experience everything it has to offer for yourself.
Survey Methodology
METHODOLOGY
- This data for this report was collected using an online survey between 20th December 2024 – 11th
January 2025
- Sample was sourced via online panels
- Countries included – Germany, Italy, Netherlands, Saudi Arabia, Spain, UK
SAMPLE DEFINITION
- PWT2D – Adults who have been diagnosed with Type 2 Diabetes
- Health Care Professionals (HCPs) – People who work in healthcare as Primary Care Generalist/
Specialist/Nurses, Primary Care Network Business Managers/Pharmacists, Consultant Endocrinologists,
Diabetes Specialist Nurse/Midwife, Diabetologist or Payors and care for Type 2 Diabetes patients
SAMPLE SIZE
- PWT2D (patients) – Germany (n=312), Italy (n=310), Netherlands (n=309) Saudi Arabia (n=309), Spain(n=310), UK (n=312), EMEA total (n=1,862)
- Health Care Professionals – Germany (n=110), Italy (n=110), Netherlands (n=107) Saudi Arabia (n=115),Spain (n=112), UK (n=110) , EMEA total (n=664)